MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights Analysis 2024: Focus on 10 ML1 Inhibitor Drug In Clinical Trials, Insight By Company, Indication and Phase
August 26, 2024 11:02 ET
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights 2024" report has been added to ResearchAndMarkets.com's offering. ...
CenExel Announces Ryan Brooks as Executive Chairman & Interim CEO
August 12, 2024 09:10 ET
|
CenExel Clinical Research
Salt Lake City, UT, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CenExel, a leading clinical research site network, proudly announces the appointment of Ryan Brooks as Executive Chairman of the Board and...
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
August 06, 2024 08:00 ET
|
Science 37, Inc.
Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials.
Understanding Pharmacovigilance Regulations in Asia-Pacific: 2-Day Training Course (Online) October 8-9, 2024 - RPPV (QPPV), PSMF, RMP, and Other Related Regulations
August 05, 2024 04:24 ET
|
Research and Markets
Dublin, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The "Understanding Pharmacovigilance Regulations in APAC Training Course" conference has been added to ResearchAndMarkets.com's offering. ...
Registration Now Open for the 2025 MDA Clinical & Scientific Conference Featuring the Latest Innovations in Neuromuscular Disease Research and Care with Global Leaders, March 16-19 in Dallas, TX
July 30, 2024 11:53 ET
|
Muscular Dystrophy Association
New York, July 30, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), convener of the largest global gathering of the neuromuscular disease community, announced today that...
Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
July 18, 2024 08:00 ET
|
Science 37, Inc.
Science 37 enrolls 65 patients per month for its sponsor's Phase 3 infectious disease clinical trial.
First patient dosed in Phase 3 Gliofocus Study for newly diagnosed glioblastoma patients at the Ivy Brain Tumor Center
July 17, 2024 08:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, July 17, 2024 (GLOBE NEWSWIRE) -- Gliofocus is a global, registrational, randomized, controlled Phase 3 clinical trial comparing niraparib vs temozolomide in newly diagnosed...
Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study
July 10, 2024 09:05 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., July 10, 2024 (GLOBE NEWSWIRE) -- With groundbreaking creativity and breathtaking speed, this phase 3 competition, funded by Innovate UK, the UK’s innovation agency, is supporting...
Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
July 02, 2024 08:00 ET
|
Bionano Laboratories
At a sponsored workshop, Su Yang from The University of Texas MD Anderson Cancer Center will present case studies that demonstrate the ability of the optical genome mapping (OGM) workflow to detect...
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
June 27, 2024 09:41 ET
|
Science 37, Inc.
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities.